biotech / news / / Reuters
Ajax's drug works by blocking JAK2, a signaling protein that helps drive several blood cancers.
Ajax's lead drug, AJ1-11095, targets JAK2 with a novel binding mechanism not seen in current treatments.
KEY POINTS
- Lilly's acquisition includes milestones-based payments in addition to an upfront fee for Ajax.
- AJ1-11095 is being developed for both myelofibrosis and polycythemia vera indications.
- The new mechanism may help AJ1-11095 work in patients unresponsive to existing therapies.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →